Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy. ICI therapy is generally better tolerated than cytotoxic chemotherapy; however, hematological adverse events (AEs) have not been fully analyzed. Hence, we performed a meta-analysis to evaluate the incidence a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohashi, Takuma, Takase-Minegishi, Kaoru, Maeda, Ayaka, Hamada, Naoki, Yoshimi, Ryusuke, Kirino, Yohei, Teranaka, Hiroshi, Kunimoto, Hiroyoshi, Hagihara, Maki, Matsumoto, Kenji, Namkoong, Ho, Horita, Nobuyuki, Nakajima, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181326/
https://www.ncbi.nlm.nih.gov/pubmed/37187501
http://dx.doi.org/10.14740/jh1090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181326/
https://www.ncbi.nlm.nih.gov/pubmed/37187501
http://dx.doi.org/10.14740/jh1090

Ejemplares similares